Safety Shot Expands into Nootropics and Sleep Aid Markets

Safety Shot ( (SHOT) ) has issued an update.

On June 3, 2025, Safety Shot, Inc. announced the initiation of research and development for new product lines targeting the nootropics and sleep aid markets. This strategic expansion leverages the company’s expertise from its Sure Shot™ product to create innovative solutions aimed at cognitive enhancement and restorative sleep. The development phase is underway, with prototypes expected later this year, positioning Safety Shot to potentially gain substantial market share in these rapidly growing sectors.

Spark’s Take on SHOT Stock

According to Spark, TipRanks’ AI Analyst, SHOT is a Neutral.

Safety Shot’s overall stock score is primarily impacted by its weak financial performance and negative technical indicators, which indicate significant operational and market challenges. However, positive corporate events, including strategic partnerships and acquisitions, provide some optimism for future growth. Immediate improvements in financial health and market strategy are essential for a stronger investment outlook.

To see Spark’s full report on SHOT stock, click here.

More about Safety Shot

Safety Shot, Inc. is a wellness and dietary supplement company known for its patented product, Sure Shot™, which lowers blood alcohol content by supporting its metabolism while enhancing clarity, energy, and overall mood. The company is expanding its market focus by introducing business-to-business sales of Sure Shot to distributors, retailers, restaurants, and bars throughout 2025.

Average Trading Volume: 1,327,435

Technical Sentiment Signal: Sell

Current Market Cap: $20.15M

See more insights into SHOT stock on TipRanks’ Stock Analysis page.